Videx Ec
Didanosine tablets for HIV-1 infection. It blocks the virus from copying its genetic material.
- Category
- HIV Management
- Active ingredient
- Didanosine
- Route
- Oral use
- Form
- Tablet
- Strengths
- 100mg
Prescription and consultation requirements for Videx Ec vary by destination and are determined by the fulfilment partner.
Videx Ec details
- Alternative names
- didanosine
- Therapeutic class
- Nucleoside Reverse Transcriptase Inhibitor (NRTI)
- Pharmacological class
- Antiretroviral
- Contraindications
- concurrent use of allopurinol or ribavirin; severe hepatic impairment
- Minor side effects
- diarrhoea; nausea; headache
- Moderate side effects
- peripheral neuropathy; abdominal pain; elevated amylase
- Dosage forms
- Tablet
- Administration route
- Oral use
- Supply category
- Prescription-only medicine (POM)
- Manufacturer
- Bristol-Myers Squibb
- Onset Time
- 2–4 weeks
- Duration
- 12–24 hours
- Storage instructions
- Store below 25°C. Keep dry.
- Drug interactions
- Allopurinol; Ribavirin; Tenofovir
- Age restrictions
- Approved for paediatric and adult populations.
Serious side effects
severe acute pancreatitis, requires immediate medical attention; lactic acidosis, requires immediate medical attention; severe hepatomegaly, requires immediate medical attention
Patient summary
Didanosine tablets for HIV-1 infection. It blocks the virus from copying its genetic material.
Mechanism of action
Incorporates into growing viral DNA, acting as a chain terminator to prevent HIV reverse transcription.
Pregnancy and breastfeeding
Pregnancy: Suitability during pregnancy depends on the specific medicine and individual circumstances. Confirm with a qualified clinician or pharmacist before use. Breastfeeding: Avoid to prevent viral transmission.